202 related articles for article (PubMed ID: 32811334)
1. Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice.
Yin Y; Li B; Zhou L; Luo J; Liu X; Wang S; Lu Q; Tan W; Chen Z
Emerg Microbes Infect; 2020 Dec; 9(1):1933-1942. PubMed ID: 32811334
[TBL] [Abstract][Full Text] [Related]
2. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein.
Luo J; Zheng D; Zhang W; Fang F; Wang H; Sun Y; Ding Y; Xu C; Chen Q; Zhang H; Huang D; Sun B; Chen Z
Virol J; 2012 Nov; 9():286. PubMed ID: 23173785
[TBL] [Abstract][Full Text] [Related]
3. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.
Huang B; Wang W; Li R; Wang X; Jiang T; Qi X; Gao Y; Tan W; Ruan L
Virol J; 2012 Dec; 9():322. PubMed ID: 23272943
[TBL] [Abstract][Full Text] [Related]
4. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
[TBL] [Abstract][Full Text] [Related]
5. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
6. An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge.
Saleh M; Nowroozi J; Farahmand B; Fotouhi F
Biotechnol Lett; 2020 Jul; 42(7):1147-1159. PubMed ID: 32152828
[TBL] [Abstract][Full Text] [Related]
7. Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.
Kwak C; Nguyen QT; Kim J; Kim TH; Poo H
J Microbiol Biotechnol; 2021 Feb; 31(2):304-316. PubMed ID: 33263336
[TBL] [Abstract][Full Text] [Related]
8. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
9. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.
Wang BZ; Gill HS; He C; Ou C; Wang L; Wang YC; Feng H; Zhang H; Prausnitz MR; Compans RW
J Control Release; 2014 Mar; 178():1-7. PubMed ID: 24417966
[TBL] [Abstract][Full Text] [Related]
10. Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine.
Yao Y; Wang H; Chen J; Shao Z; He B; Chen J; Lan J; Chen Q; Chen Z
Emerg Microbes Infect; 2019; 8(1):45-54. PubMed ID: 30866759
[TBL] [Abstract][Full Text] [Related]
11. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.
Wang W; Huang B; Jiang T; Wang X; Qi X; Gao Y; Tan W; Ruan L
PLoS One; 2012; 7(12):e52488. PubMed ID: 23285063
[TBL] [Abstract][Full Text] [Related]
12. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
[TBL] [Abstract][Full Text] [Related]
13. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.
Lamere MW; Moquin A; Lee FE; Misra RS; Blair PJ; Haynes L; Randall TD; Lund FE; Kaminski DA
J Virol; 2011 May; 85(10):5027-35. PubMed ID: 21367900
[TBL] [Abstract][Full Text] [Related]
14. Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.
Kim MH; Kang JO; Kim JY; Jung HE; Lee HK; Chang J
Antiviral Res; 2019 Mar; 163():19-28. PubMed ID: 30639307
[TBL] [Abstract][Full Text] [Related]
15. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes.
Fan X; Hashem AM; Chen Z; Li C; Doyle T; Zhang Y; Yi Y; Farnsworth A; Xu K; Li Z; He R; Li X; Wang J
Mucosal Immunol; 2015 Jan; 8(1):211-20. PubMed ID: 25052763
[TBL] [Abstract][Full Text] [Related]
16. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
17. Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
Sabbaghi A; Zargar M; Zolfaghari MR; Motamedi-Sedeh F; Ghaemi A
Arch Virol; 2021 Feb; 166(2):545-557. PubMed ID: 33409549
[TBL] [Abstract][Full Text] [Related]
18. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
19. Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice.
Joe PT; Christopoulou I; van Hoecke L; Schepens B; Ysenbaert T; Heirman C; Thielemans K; Saelens X; Aerts JL
J Transl Med; 2019 Jul; 17(1):242. PubMed ID: 31345237
[TBL] [Abstract][Full Text] [Related]
20. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
